Уноси

• Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways (2016-09)

  M. Ermisch, A. Bucsics, P. Vella Bonanno, F. Arickx, A. Bybau, T. Bochenek, M. van der Casteele, E. Digene, J. Furst, K. Garuoliene, M. van der Graff, J. Gulbinovic, A. Haycox, J. Jones, R. Joppi, O. Laius, I. Langner, A. Martin, V. Marković Peković, L. McCullagh, E. Magnusson, E. Nilsen, G. Selke, C. Sermet, S. Simoens, R. Sauremann, A. Schuurman, R. Ramos, V. Vlahović-Palčevski, C. Zara, B. Godman, Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways, Frontiers in Pharmacology, Vol. 7, pp. 1 - 9, Sep, 2016

• Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation (2017-08)

  P. Vella Bonanno, M. Ermisch, B. Godman, A. Martin, J. Van Den Bergh, L. Bezmelnitsyna, A. Bucsics, F. Arickx, A. Bybau, T. Bochenek, M. van der Casteele, E. Diogene, I. Eriksson, J. Furst, M. Gad, I. Greičiute-Kuprijanov, M. van der Graff, J. Gulbinovic, J. Jones, R. Joppi, M. Kalaba, O. Laius, I. Langner, I. Mardare, V. Marković Peković, E. Magnusson, O. Melien, D. Meshkov, G. Petrova, G. Selke, C. Sermet, S. Simoens, A. Schuurman, R. Ramos, J. Rodrigues, C. Zara, E. Zebedin-Brandl, A. Haycox, Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation, Frontiers in Pharmacology, Vol. 8, pp. 1 - 13, Aug, 2017

• Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018-12)

  B. Godman, A. Bucsics, P. Vella Bonanno, W. Oortwijn, C. Rothe, A. Ferrario, S. Bosselli, A. Hill, A. Martin, S. Simoens, A. Kurdi, M. Gad, J. Gulbinovic, A. Timoney, T. Bochenek, A. Salem, I. Hoxha, R. Sauermann, A. Massele, A. Guerra Junior, G. Petrova, Z. Mitkova, G. Achniotou, O. Laius, C. Sermet, G. Selke, V. Kourafalos, J. Yfantopoulos, E. Magnusson, R. Joppi, M. Oluka, H. Kwon, A. Jakupi, F. Kalemeera, J. Fadare, O. Melien, M. Pomorski, M. Wladysiuk, V. Marković Peković, I. Mardare, D. Meshkov, T. Novakovic, J. Furst, D. Tomek, C. Zara, E. diogene, J. Meyer, R. Malmstrom, B. Wettermark, Z. Matsebula, S. Campbell, A. Haycox, Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets, Frontiers in public health, Vol. 6, No. Article 328, pp. 1 - 21, Dec, 2018

• Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA (2019-02)

  P. Vella Bonanno, A. Bucsics, S. Simoens, A. Martin, W. Oortwijn, J. Gulbinovic, C. Rothe, A. Timoney, A. Ferrario, M. Gad, A. Salem, I. Hoxha, R. Sauremann, M. Kamusheva, M. Dimitrova, G. Petrova, O. Laius, G. Selke, V. Kourafalos, J. Yfantopoulos, E. Magnusson, R. Joppi, A. Jakupi, T. Bochenek, M. Wladysiuk, C. Furtado, V. Marković Peković, I. Mardare, D. Meshkov, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, A. Haycox, S. Campbell, B. Godman, Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 19, No. 3, pp. 251 - 261, Feb, 2019

• Ongoing Strategies to Improve the Management of Upper Respiratory Tract Infections and Reduce Inappropriate Antibiotic Use Particularly Among Lower and Middle-Income Countries: Findings and Implications for the Future (2020-02)

  B. Godman, M. Haque, J. McKimm, M. Abu Bakar, J. Sneddoh, J. Wale, S. Campbell, A. Martin, I. Hoxha, V. Abilova, B. Paramadhas, P. Mpinda-Joseph, M. Matome, L. Lovato, I. Sefah, A. Kurdi, S. Opanga, A. Jakupi, Z. Saleem, M. Hassali, D. Kibule, J. Fadare, T. Bochenek, C. Rothe, J. Fraeyman, V. Marković Peković, Љ. Бојанић, N. Schellack, J. Meyer, Z. Matsebula, T. Phuong, B. Thanh, S. Jan, A. Kalungia, S. Matpuri-Ziyowera, M. Sartelli, R. Hill, Ongoing Strategies to Improve the Management of Upper Respiratory Tract Infections and Reduce Inappropriate Antibiotic Use Particularly Among Lower and Middle-Income Countries: Findings and Implications for the Future, CURRENT MEDICAL RESEARCH AND OPINION, Vol. 36, No. 2, pp. 301 - 327, Feb, 2020

• Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries (2020-02)

  B. Godman, H. McCabe, T. Leong, D. Mueller, A. Martin, I. Hoxha, J. Mwita, G. Rwegerera, A. Massele, J. Costa, R. Nascimento, L. Lovato, K. Tachkov, P. Milushewa, O. Patrick, L. Niba, O. Laius, I. Sefah, S. Abdulsalim, F. Soleymani, L. Achieng, A. Guantai, M. Oluka, A. Jakupi, K. Logviss, M. Hassali, D. Kibule, F. Kalemeera, M. Mubita, I. Mardare, A. Alrasheedy, J. Furst, D. Tomek, V. Marković Peković, T. Phuong, B. Thanh, A. Kalungia, T. Zaranyika, N. Masuka, I. Olaru, J. Wale, R. Hill, A. Kurdi, A. Timoney, S. Campbell, J. Meyer, Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 20, No. 1, pp. 1 - 26, Feb, 2020

• Variation in the prices of oncology medicines across Europe and the implications for the future (2021-02)

  B. Godman, S. Simoens, A. Kurdi, G. Selke, J. Yfantopoulos, A. hill, J. Gulbinovic, A. Martin, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Selke Krulichova, E. Allocati, I. Hoxha, A. Malaj, C. Hierlander, A. Nachtnebel, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, R. Plisko, M. Wladysiuk, V. Marković Peković, I. Mardare, T. Novakovic, M. Parker, J. Furst, D. Tomek, K. Banasova, M. Obach Cortadellas, C. Zara, C. Pontes, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, D. Wong-Rieger, S. Campbell, R. Hill, Variation in the prices of oncology medicines across Europe and the implications for the future, Generics and Biosimilars Initiative Journal, Vol. 10, No. 2, pp. 72 - 82, Feb, 2021

• Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021-03)

  B. Godman, A. Hill, S. Simoens, G. Selke, I. Selke Krulichova, C. Zampirolli, A. Martin, W. Oortwijn, A. Timoney, L. Gustafsson, L. Vončina, H. Kwon, J. Gulbinovic, D. Gotham, J. Wale, W. da Silva, T. Bochenek, A. Kurdi, E. Allocati, O. Ogunleye, J. Meyer, I. Hoxha, A. Malaj, C. Hierlander, R. Sauremann, W. Hamelinck, G. Petrova, O. Laius, I. Langner, J. Yfantopoulos, R. Joppi, A. Jakupi, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, M. Wladysiuk, V. Marković Peković, I. Mardare, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, C. Pontes, S. McTaggart, T. Laba, O. Melien, D. Wong-Rieger, S. Bae, R. Hill, Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 21, No. 4, pp. 527 - 540, Mar, 2021

• Evidence-based public policy making for medicines across countries: findings and implications for the future (2021-08)

  B. Godman, J. Fadare, H. Kwon, C. Zampirolli, A. Kurdi, I. Piassi, D. Kibule, I. Hoxha, S. Opanga, Z. Saleem, T. Bochenek, V. Marković Peković, I. Mardare, A. Kalungia, S. Campbell, E. Allocati, A. Pisana, A. Martin, J. Meyer, Evidence-based public policy making for medicines across countries: findings and implications for the future, Journal of Comparative Effectiveness Research, Vol. 10, No. 12, pp. 1019 - 1052, Aug, 2021

• Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues (2022-03)

  B. Godman, B. Tubić, E. Allocati, M. Wladysiuk, S. McTaggart, A. Kurdi, M. Haque, S. McBride-Stewart, F. Kalemeera, A. Massele, I. Hoxha, V. Marković Peković, G. Petrova, K. Tachkov, O. Laius, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, P. Vella Bonanno, J. Rutkowski, I. Mardare, J. Furst, C. Pontes, C. Zara, M. Turu Pedrola, F. Akter, H. Kwon, A. Martin, R. Banzi, J. Wale, J. Gulbinovic, Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues, Journal of Applied Pharmaceutical Science, Vol. 12, No. 3, pp. 055 - 072, Mar, 2022